Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.

ABSTRACT:

Background

No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer.

Methods

A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively.

Results

Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% an

SUBMITTER: Saito T 

PROVIDER: S-EPMC10991393 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature